Literature DB >> 34115714

Preclinical Safety of a 3D-Printed Hydroxyapatite-Demineralized Bone Matrix Scaffold for Spinal Fusion.

Mark Plantz1,2, Joseph Lyons1,2, Jonathan T Yamaguchi1,2, Allison C Greene1,2, David J Ellenbogen1,2, Mitchell J Hallman1,2, Vivek Shah1,2, Chawon Yun1,2, Adam E Jakus3, Daniele Procissi4, Silvia Minardi1,2, Ramille N Shah2,3, Wellington K Hsu1,2, Erin L Hsu1,2.   

Abstract

STUDY
DESIGN: Prospective, randomized, controlled preclinical study.
OBJECTIVE: The objective of this study was to compare the host inflammatory response of our previously described hyperelastic, 3D-printed (3DP) hydroxyapatite (HA)-demineralized bone matrix (DBM) composite scaffold to the response elicited with the use of recombinant human bone morphogenetic protein-2 (rhBMP-2) in a preclinical rat posterolateral lumbar fusion model. SUMMARY OF BACKGROUND DATA: Our group previously found that this 3D-printed HA-DBM composite material shows promise as a bone graft substitute in a preclinical rodent model, but its safety profile had yet to be assessed.
METHODS: Sixty female Sprague-Dawley rats underwent bilateral posterolateral intertransverse lumbar spinal fusion using with the following implants: 1) type I absorbable collagen sponge (ACS) alone; 2) 10 μg rhBMP-2/ACS; or 3) the 3DP HA-DBM composite scaffold (n = 20). The host inflammatory response was assessed using magnetic resonance imaging, while the local and circulating cytokine expression levels were evaluated by enzyme-linked immunosorbent assays at subsequent postoperative time points (N = 5/time point).
RESULTS: At both 2 and 5 days postoperatively, treatment with the HA-DBM scaffold produced significantly less soft tissue edema at the fusion bed site relative to rhBMP-2-treated animals as quantified on magnetic resonance imaging. At every postoperative time point evaluated, the level of soft tissue edema in HA-DBM-treated animals was comparable to that of the ACS control group. At 2 days postoperatively, serum concentrations of tumor necrosis factor-α and macrophage chemoattractant protein-1 were significantly elevated in the rhBMP-2 treatment group relative to ACS controls, whereas these cytokines were not elevated in the HA-DBM-treated animals.
CONCLUSION: The 3D-printed HA-DBM composite induces a significantly reduced host inflammatory response in a preclinical spinal fusion model relative to rhBMP-2.Level of Evidence: N/A.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34115714      PMCID: PMC8765284          DOI: 10.1097/BRS.0000000000004142

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  46 in total

Review 1.  The role of human bone morphogenetic proteins in spinal fusion.

Authors:  D A Zlotolow; A R Vaccaro; M L Salamon; T J Albert
Journal:  J Am Acad Orthop Surg       Date:  2000 Jan-Feb       Impact factor: 3.020

Review 2.  Biomaterials: where we have been and where we are going.

Authors:  Buddy D Ratner; Stephanie J Bryant
Journal:  Annu Rev Biomed Eng       Date:  2004       Impact factor: 9.590

3.  Increased swelling complications associated with off-label usage of rhBMP-2 in the anterior cervical spine.

Authors:  Joseph D Smucker; John M Rhee; Kern Singh; S Tim Yoon; John G Heller
Journal:  Spine (Phila Pa 1976)       Date:  2006-11-15       Impact factor: 3.468

Review 4.  A clinical perspective of IL-1β as the gatekeeper of inflammation.

Authors:  Charles A Dinarello
Journal:  Eur J Immunol       Date:  2011-05       Impact factor: 5.532

5.  Progress in orthopedic biomaterials and drug delivery.

Authors:  Blanka Sharma; Shyni Varghese
Journal:  Drug Deliv Transl Res       Date:  2016-04       Impact factor: 4.617

6.  Effects of Diclofenac Sodium on BMP-induced Inflammation in a Rodent Model.

Authors:  Shuai Ye; Jong-Han Yim; Jung-Ryul Kim; Kyu Yun Jang; Hongen Wang; Jeffrey C Wang; Kwang-Bok Lee
Journal:  Spine (Phila Pa 1976)       Date:  2015-07-15       Impact factor: 3.468

7.  Nanocomposite therapy as a more efficacious and less inflammatory alternative to bone morphogenetic protein-2 in a rodent arthrodesis model.

Authors:  Wellington K Hsu; Mahesh Polavarapu; Rehan Riaz; Gilbert C Roc; Stuart R Stock; Zachary S Glicksman; Jason H Ghodasra; Erin L Hsu
Journal:  J Orthop Res       Date:  2011-05-16       Impact factor: 3.494

Review 8.  Chemical degradation of peptides and proteins in PLGA: a review of reactions and mechanisms.

Authors:  M L Houchin; E M Topp
Journal:  J Pharm Sci       Date:  2008-07       Impact factor: 3.534

9.  Does fusion status after posterior lumbar interbody fusion affect patient-based QOL outcomes? An evaluation performed using a patient-based outcome measure.

Authors:  Takahiro Makino; Takashi Kaito; Hiroyasu Fujiwara; Takahiro Ishii; Motoki Iwasaki; Hideki Yoshikawa; Kazuo Yonenobu
Journal:  J Orthop Sci       Date:  2014-06-12       Impact factor: 1.601

10.  In vivo biocompatibility of PLGA-polyhexylthiophene nanofiber scaffolds in a rat model.

Authors:  Anuradha Subramanian; Uma Maheswari Krishnan; Swaminathan Sethuraman
Journal:  Biomed Res Int       Date:  2013-07-23       Impact factor: 3.411

View more
  1 in total

Review 1.  Novel Approaches Guiding the Future of Spinal Biologics for Bone Regeneration.

Authors:  Eileen N Phan; Wellington K Hsu
Journal:  Curr Rev Musculoskelet Med       Date:  2022-04-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.